Business Wire

Kezzler and Toppan America Announce Strategic Partnership in North America


Kezzler AS, a global leader in making brands unique and interactive, and Toppan Printing Company America, Inc. (Toppan America), a subsidiary of Toppan Printing Co., Ltd and a global printing company, today announced a strategic partnership ( in North America to market a combined printing and cost-effective serialization technology to manage global brand protection, supply chain and consumer engagement.

“Toppan carried out an extensive evaluation of the market and technologies for serialization and believe Kezzler provides the most cost-effective and scalable solution for our global customers. Our combined solution empowers the luxury, fragrance, beauty and health and wellness markets with new and near real time opportunities for consumer engagement, marketing, and consumer intelligence,” said Masa Tatewaki, president of Toppan America. “Toppan’s wide range of security technologies complemented by Kezzler’s software solution will also provide many of the world’s recognized brands with multiple layers of defense against counterfeit, tampering and diversion.”

The need for innovative and superior anti-counterfeit technologies is growing rapidly. Estimates on the cost of counterfeiting in the US range from $250 billion to $600 billion annually and estimates of global trade in counterfeit goods exceeds $1.7 trillion in 2015. The US alone has verifiable experience of 23,140 - counterfeit related seizures in 2014 and $1.22 billion as the total value of counterfeit seizures (MSRP) in 2014.

According to the Organisation for Economic Co-operation and Development 2016:

  • Imports of counterfeit and pirated goods are worth nearly half a trillion dollars a year, or around 2.5% of global imports
  • The total value of imported fake goods worldwide was $461 billion in 2013 (total imports in world trade of $17.9 trillion)
  • Up to 5 percent of goods imported into the European Union are fakes
  • US, Italian and French brands the hardest hit
  • In many cases, the proceeds of counterfeit trade go towards organized crime.
  • Most fake goods originate in middle income or emerging countries, with China the top producer

The International Chamber of Commerce (ICC) puts the cost of lost tax revenue and additional welfare spending due to counterfeit goods up to $125 billion in developed countries alone. And 2.5 million jobs lost as a result of counterfeit products.

Using encryption technology and a cloud–based solution, brand owners can create fully customized loyalty and information programs through a unique identifier (UID). Consumers only have to text, snap or app the code on the product. At that point, the brand owner will in near real time know who authenticated the product and where they are located. This interaction provides brand owners with unique information about the consumer and the consumers’ unique information about the product.

“Kezzler is delighted to join forces with another global company with cutting edge IT information management and security technology. As part of our aggressive growth the next few years and the huge market opportunity in brand protection and consumer engagement, a key strategy is to partner with the biggest and best printing and packaging companies in the world. Toppan’s global footprint and reputation is very well known and respected and the two companies are committed to create a new serialization standard for global companies,” commented Thomas Kormendi, CEO of Kezzler.

About Kezzler

Kezzler AS is a global leader in serialization technologies and operated platform designed for industrial scale. Kezzler’s mission is to standardize serialization and change global business practices by making product items digitally unique and interactive. Kezzler has offices in United States, India, Austria, the Netherlands and China. To learn more about Kezzler, visit

About Toppan

TOPPAN PRINTING CO., LTD. Founded in 1900 Toppan has leveraged expertise in printing securities, including banknotes, Border control documents and accumulated information processing technologies supported by advanced security. Toppan operates globally and employs approx. 49,000 people. Fiscal year ended March 31, 2015 Toppan posted revenues of approx. US $14 billion. Information & Communication segment provides Secure Business such as printing of security related products, passbooks, integrated circuit (IC) cards, also provides Marketing and Content Business, Living & Industry segment provides Packaging, Interior Décor Materials, and Functional Product & Energy Related products. ; Electronics segment offers Display Related and Semiconductor Related products. For more information visit /

Contact information

Kezzler AS
Paul Laland, 1-415-519-6610
Brian Healy, 1-212-489-7740 ext. 515

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on